| ID | JOS-s41120-026-00170-6 |
| 著者:名前 | |
| 著者:別形式 | Lescano, Israel Judah / Sani, Janid / Tabornal, Anne Melanie / Arce, Jr Florencio / See, Lee Gerard / 小玉, 菜央 / 井上, 裕 |
| 著者:カナ | |
| 著者:所属 | University of San Carlos, Department of Pharmacy, School of Health Care Professions ; University of San Carlos, Pharmaceutical Research and Drug Development Laboratories, Department of Pharmacy, School of Health Care Professions / University of San Carlos, Department of Pharmacy, School of Health Care Professions / University of San Carlos, Department of Pharmacy, School of Health Care Professions / University of San Carlos, Department of Pharmacy, School of Health Care Professions ; University of San Carlos, Pharmaceutical Research and Drug Development Laboratories, Department of Pharmacy, School of Health Care Professions ; National Research Council of the Philippines, Pharmaceutical Sciences Division / University of San Carlos, Department of Pharmacy, School of Health Care Professions ; University of San Carlos, Pharmaceutical Research and Drug Development Laboratories, Department of Pharmacy, School of Health Care Professions ; National Research Council of the Philippines, Pharmaceutical Sciences Division / Josai University, Laboratory of Nutri-Pharmacotherapeutics Management, Faculty of Pharmacy and Pharmaceutical Sciences / Josai University, Laboratory of Nutri-Pharmacotherapeutics Management, Faculty of Pharmacy and Pharmaceutical Sciences |
| 著者:所属(別形式) | University of San Carlos, Department of Pharmacy, School of Health Care Professions ; University of San Carlos, Pharmaceutical Research and Drug Development Laboratories, Department of Pharmacy, School of Health Care Professions / University of San Carlos, Department of Pharmacy, School of Health Care Professions / University of San Carlos, Department of Pharmacy, School of Health Care Professions / University of San Carlos, Department of Pharmacy, School of Health Care Professions ; University of San Carlos, Pharmaceutical Research and Drug Development Laboratories, Department of Pharmacy, School of Health Care Professions ; National Research Council of the Philippines, Pharmaceutical Sciences Division / University of San Carlos, Department of Pharmacy, School of Health Care Professions ; University of San Carlos, Pharmaceutical Research and Drug Development Laboratories, Department of Pharmacy, School of Health Care Professions ; National Research Council of the Philippines, Pharmaceutical Sciences Division / 城西大学薬学部栄養治療学研究室 / 城西大学薬学部栄養治療学研究室 |
| 著者版フラグ | publisher |
| 出版地 | London |
| 出版者 | Springer |
| 電子ISSN | 23649534 |
| 掲載誌名 | |
| 巻 | 12 |
| 号 | 33 |
| 刊行年月 | 2026 |
| 開始ページ | 1 |
| 終了ページ | 12 |
| コンテンツ作成日 | 2026-04-30 |
| コンテンツ登録日 | 2026-07-07 |
| 識別番号:DOI | info:doi/10.1186/s41120-026-00170-6 |
| 識別番号:DOI(リンク) | |
| 抄録 | This study prepared a paracetamol-β-cyclodextrin inclusion complex via co-precipitation method to address the structural and organoleptic challenges of high-dose orodispersible films. Characterization using DSC, FTIR, and NMR confirmed successful guest–host interaction, while 1H-NMR established a 1:1 stoichiometry. Importantly, PXRD provides the first molecular evidence of a channel-type crystalline habit, with new diffraction peaks at 2θ = 15.4º, 20.3º, and 24.3º. The complex achieved an encapsulation efficiency of 41.94% ± 4.41%. In vitro dissolution studies revealed a regulated, biphasic drug release of up to 81. 41% ± 9.8% after 60 min and a 30-min dissolution efficiency of 60.06% ± 6.92% (p = 0.003). Furthermore, it demonstrated initial antipyretic activity in brewer’s yeast induced pyrexia in Sprague–Dawley rats. However, the regulated release from the complex resulted in diminished pharmacologic activity at later stages of the assay compared to neat APAP. These findings identify a critical trade off between the molecular shielding provided by the complex’s architecture and the kinetic barriers to reaching optimal clinical efficacy. This study establishes a foundational blueprint for stabilizing BCS class III drugs in space constrained platforms and underscores the necessity of optimizing critical process parameters to increase the therapeutic payload within the BCD framework. |
| キーワード | |
| 言語 | eng |
| 資源タイプ | text |
| ジャンル | |
| フォーマット | application/pdf |
| 権利 | ©2026 Springer |
| このアイテムを表示する:本文(pdf) |  ( 2.6MB) ダウンロード回数: 回 |
| このアイテムを表示する:URI | |